Trends and Utilization of Laser Prostatectomy in Ambulatory Surgical Procedures for the Treatment of Benign Prostatic Hyperplasia in New York State (2000-2011)

Journal of Endourology

Volumn 29, Issue 6, 2015, Pages 700-706

  Chughtai, Bilal I ^a   Simma Chiang, Vannita ^a   Lee, Richard ^a   Isaacs, Abby ^a   Te, Alexis E ^a   Kaplan, Steven A ^a   Sedrakyan, Art ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AMBULATORY SURGERY; ARTICLE; COMORBIDITY; ELECTROLYTE DISTURBANCE; HUMAN; LASER COAGULATION; LASER PROSTATECTOMY; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAID; PATIENT SAFETY; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PROSTATE HYPERTROPHY; TRANSURETHRAL RESECTION; CLINICAL PRACTICE; OUTCOME ASSESSMENT; PROCEDURES; PROSTATIC HYPERPLASIA; STATISTICS AND NUMERICAL DATA; TRENDS; UNITED STATES; UTILIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMBULATORY SURGICAL PROCEDURES; HUMANS; LASER THERAPY; MALE; NEW YORK; OUTCOME ASSESSMENT (HEALTH CARE); PRACTICE PATTERNS, PHYSICIANS'; PROSTATIC HYPERPLASIA; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 84931098904     PISSN: 08927790     EISSN: 1557900X     Source Type: Journal    
DOI: 10.1089/end.2014.0692     Document Type: Article

References (23)

1. Lu-Yao GL, Barry MJ, Chang CH, et al. Transurethral resection of the prostate among Medicare beneficiaries in the United States: Time trends and outcomes. Prostate patient outcomes research team (PORT). Urology 1994;44:692-698.
2. Wasson JH, Bubolz TA, Lu-Yao GL, et al. Transurethral resection of the prostate among Medicare beneficiaries: 1984-1997. For the patient outcomes research team for prostatic diseases. J Urol 2000;164:1212-1215.
3. Izard J, Nickel JC. Impact of medical therapy on transurethral resection of the prostate: Two decades of change. BJU Int 2011;108:89-93.
4. Roehrborn CG, Siami P, Barkin J, et al.; the CombAT Study Group. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008;179:616-621; discussion 621.
5. Roehrborn CG. BPH progression: Concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 2008;101(Suppl 3):17-21.
6. Malaeb BS, Yu X, McBean AM, et al. National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000-2008). Urology 2012;79:111-1117.
7. Kaplan SA. Editorial Comment Re: National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000-2008). J Urol 2013;189:616-617.
8. Hueber PA, Zorn KC. Canadian trend in surgical management of benign prostatic hyperplasia and laser therapy from 2007-2008 to 2011-2012. Can Urol Assoc J 2013;7:E582-E586.
9. Ghani, KR, Zheng K, Wei JT, et al. Harnessing big data for health care and research: Are urologists ready? Euro Urol 2014 Epub ahead of print; DOI: 10.1016/j.eururo.2014.07.032
10. Statewide Planning and Research Cooperative System (SPARCS), New York. www.health.state.ny.us/nysdoh/sparcs/sparcs.htm Accessed: September 22, 2014.
11. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27.
12. van Walraven C, Austin PC, Jennings A, et al. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care 2009;47:626-633.
13. Rassen J, Doherty M, Huang W, Schneeweiss S. Using the Pharmacoepi Toolbox in SAS. Boston, 2013. www.hdpharmacoepi.org Accessed: September 22, 2014.
14. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011;10:150-161.
15. Al-Ansari A, Younes N, Sampige VP, et al. GreenLight HPS 120-W Laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: A randomized clinical trial with midterm follow-up. Eur Urol 2010;58:349-355.
16. Capitan C, Blazquez C, Martin MD, et al. GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: A randomized clinical trial with 2-year follow-up. Eur Urol 2011;60:734-739.
17. Kumar A, Vasudeva P, Kumar N, et al. A prospective randomized comparative study of monopolar and bipolar transurethral resection of the prostate and photoselective vaporization of the prostate in patients who present with benign prostatic obstruction: A single center experience. J Endourol 2013;27:1245-1253.
18. Lukacs B, Loeffler J, Bruyere F, et al. Photoselective vaporization of the prostate with GreenLight 120-W laser compared with monopolar transurethral resection of the prostate: A multicenter randomized controlled trial. Eur Urol 2012;61:1165-1173.
19. Bhojani N, Gandaglia G, Sood A, et al. Morbidity and mortality after benign prostatic hyperplasia surgery: Data from the American College of Surgeons National Surgical Quality Improvement Program. J Endourol 2014;28:831-840.
20. Schroeck FR, Hollingsworth JM, Hollenbeck BK, Jacobs BL, Suskind AM, Sarma AV, Wei JT. Differential adoption of laser prostatectomy for treatment of benign prostatic hyperplasia. Urology 2013;81:1177-1182.
21. Chen CH, Lin SE, Chiang PH. Outcome of GreenLight HPS laser therapy in surgically high-risk patients. Lasers Med Sci 2013;28:1297-1303.
22. Sandhu JS, Ng CK, Gonzalez RR, et al. Photoselective laser vaporization prostatectomy in men receiving anticoagulants. J Endourol 2005;19:1196-1198.
23. Eishal AM, Elamnsy HM, Elhilali MM. Transurethral laser surgery for benign prostate hyperplasia in octogenarians: Safety and outcomes. Urology 2013;81:634-639.